Schmidt Dayane, Ebrahimabadi Sima, Gomes Kauan Ribeiro de Sena, de Moura Aguiar Graziela, Cariati Tirapelle Mariane, Nacasaki Silvestre Renata, de Azevedo Júlia Teixeira Cottas, Tadeu Covas Dimas, Picanço-Castro Virginia
Regional Blood Center of the School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil.
Department of Medical Imaging, Hematology, and Clinical Oncology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
Immunother Adv. 2022 Feb 3;2(1):ltac003. doi: 10.1093/immadv/ltac003. eCollection 2022.
Cell therapy is an innovative approach that permits numerous possibilities in the field of cancer treatment. CAR-T cells have been successfully used in patients with hematologic relapsed/refractory. However, the need for autologous sources for T cells is still a major drawback. CAR-NK cells have emerged as a promising resource using allogeneic cells that could be established as an off-the-shelf treatment. NK cells can be obtained from various sources, such as peripheral blood (PB), bone marrow, umbilical cord blood (CB), and induced pluripotent stem cells (iPSC), as well as cell lines. Genetic engineering of NK cells to express different CAR constructs for hematological cancers and solid tumors has shown promising preclinical results and they are currently being explored in multiple clinical trials. Several strategies have been employed to improve CAR-NK-cell expansion and cytotoxicity efficiency. In this article, we review the latest achievements and progress made in the field of CAR-NK-cell therapy.
细胞疗法是一种创新方法，在癌症治疗领域具有众多可能性。嵌合抗原受体T细胞（CAR-T细胞）已成功应用于血液系统复发/难治性患者。然而，T细胞需要自体来源仍然是一个主要缺点。嵌合抗原受体自然杀伤细胞（CAR-NK细胞）作为一种有前景的资源出现，它使用的是同种异体细胞，可以被开发为现成可用的治疗方法。自然杀伤细胞可以从多种来源获得，如外周血（PB）、骨髓、脐带血（CB）、诱导多能干细胞（iPSC）以及细胞系。对自然杀伤细胞进行基因工程改造，使其表达针对血液系统癌症和实体瘤的不同嵌合抗原受体构建体，已显示出有前景的临床前结果，目前正在多项临床试验中进行探索。已经采用了几种策略来提高CAR-NK细胞的扩增和细胞毒性效率。在本文中，我们综述了CAR-NK细胞疗法领域取得的最新成果和进展。
